Neonicotinoid Reevaluation Timeline

Back to Neonicotinoids

Page updated 01/06/16

2009

  • Reevaluation initiated requiring studies after application of each active ingredient to determine residue levels in pollen, nectar, and leaves of certain bee attractive orchard and row crops in three different soil types. Residue study strategy included locating existing treated fields to conduct trials. Additionally, DPR required studies to determine the toxicity to honey bee larva.
  • Two presentations (March and November) to Pesticide Registration Evaluation Committee (PREC) to communicate DPR’s reevaluation status to stakeholders and public.
  • DPR collaborates and forms partnership with U.S. EPA’s Office of Pesticide Programs, and PMRA Health Canada for developing the methods and procedures (protocols) used to conduct studies on the effects of neonicotinoids that can be used across the board by all three agencies to guide their regulatory actions.
  • DPR, U.S. EPA and PMRA Health Canada have discussions with key independent bee researchers to assure that honey bee larva study protocols are guided by the best possible science to ensure the studies provide useful and reliable information.
  • Registrants begin to submit existing data to meet DPR’s data requirements (commencing in November).

2010

  • DPR prioritizes receipt and analysis of imidacloprid data due to high use relative to other neonicotinoid products.
  • DPR determined submitted existing imidacloprid data to be insufficient and required initial residue data requirements to be met.
  • Presentation to PREC in September to communicate DPR’s reevaluation status to stakeholders and public.

2011

  • Registrants remove almonds from imidacloprid labels eliminating the need for residue studies in almonds.
  • Presentation to PREC in March to communicate reevaluation activity to stakeholders and public.
  • Some imidacloprid residue study data received.

2012

  • Residue and larva toxicity study data received from all registrants (imidacloprid, thiamethoxam, clothianidin, and dinotefuran) between January and March.
  • In February and March, DPR issued its first additional data request to imidacloprid registrants as residue information provided is inconclusive because study strategy did not involve worst case scenarios. Residue study strategy modified to make controlled applications at the highest maximum application rate per year for two consecutive years. Additional trials in citrus with different soil type also required.
  • Presentation to PREC in July to communicate reevaluation activity to stakeholders and public.
  • In October, DPR requests additional residue trials using thiamethoxam.
  • Additional imidacloprid residue study data received conducted under original residue study strategy.

2013

  • Thiamethoxam residue data received.
  • Imidacloprid honey bee feeding studies conducted to determine long-term impact to honey bee hives during and after feeding using an artificial diet.
  • In May, DPR requests additional residue trials using clothianidin.
  • Almonds removed from thiamethoxam labels by registrants eliminating the need for residue studies in almonds.
  • DPR, U.S. EPA and PMRA Health Canada have discussions with key independent bee researchers to consult on higher tier full field honey bee colony measurement endpoints.
  • In August, U.S. EPA announces its pollinator protection labeling initiative which required all outdoor foliar applied neonicotinoid products to have new labeling in the marketplace by February 28, 2014. DPR centralized and expedited these label changes to mitigate foliar applications in advance of the conclusion of the reevaluation.

2014

  • Presentation to PREC in January to communicate efforts of the pollinator protection labeling initiative to stakeholders and public.
  • Thiamethoxam and clothianidin honey bee studies initiated to determine long-term impact to honey bee hives during and after feeding on an artificial diet.
  • Imidacloprid higher tier honey bee full field study conducted to determine long-term effects to honey bee colonies when placed in a treated field.
  • Imidacloprid honey bee feeding study final report received.

2015

  • Clothianidin residue data received.
  • Presentation to PREC in May to communicate DPR's reevaluation status to stakeholders and public.
  • In June and July, DPR receives final reports from imidacloprid and thiamethoxam residue trials.
  • In December, DPR receives final reports from dinotefuran honey bee larval toxicity and thiamethoxam residue trials.

2016

  • In January, U.S. EPA releases a preliminary pollinator risk assessment for imidacloprid. This document was a collaborative effort between DPR and U.S. EPA.
  • In February, DPR anticipates receiving final reports from thiamethoxam and clothianidin honey bee feeding studies and final reports from imidacloprid, thiamethoxam, and dinotefuran residue trials.
  • In February and April, DPR anticipates receiving final report from dinotefuran residue trials.
  • In June, DPR anticipates receiving thiamethoxam residue trial final reports.
  • In November, DPR anticipates receiving final reports from imidacloprid full field honey bee study, dinotefuran a residue trial, as well as, dinotefuran honey bee feeding study.
  • In December, U.S. EPA anticipates releasing the preliminary pollinator-only risk assessments for clothianidin, thiamethoxam, and dinotefuran. Additionally, U.S. EPA anticipates releasing a comprehensive risk assessment for imidacloprid, including human health and ecological risk. DPR anticipates receiving final reports from clothianidin residue trials.

2017

  • U.S. EPA anticipates releasing comprehensive risk assessments for clothianidin, thiamethoxam, and dinotefuran.

For content questions, contact:
Denise Alder
1001 I Street, P. O. Box 4015
Sacramento, CA 95812-4015
Phone: (916) 324-3522
E-mail: Denise.Alder@cdpr.ca.gov